Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study
- Author:
Daisuke AOKI
1
;
Tsutomu TABATA
;
Satoshi YANAGIDA
;
Toshiaki NAKAMURA
;
Eiji KONDO
;
Junzo HAMANISHI
;
Kenichi HARANO
;
Kosei HASEGAWA
;
Takeshi HIRASAWA
;
Kensuke HORI
;
Shinichi KOMIYAMA
;
Motoki MATSUURA
;
Hidekatsu NAKAI
;
Hiroko NAKAMURA
;
Jun SAKATA
;
Kazuhiro TAKEHARA
;
Munetaka TAKEKUMA
;
Yoshihito YOKOYAMA
;
Yoichi KASE
;
Shuuji SUMINO
;
Junpei SOEDA
;
Ai KATO
;
Ajit SURI
;
Aikou OKAMOTO
;
Toru SUGIYAMA
Author Information
- Publication Type:Original Article
- From:Journal of Gynecologic Oncology 2024;35(5):e114-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:To evaluate the long-term efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer.
Methods:This was the follow-up analysis of a phase 2, multicenter, open-label, single-arm study in Japanese women with homologous recombination-deficient, platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who had completed 3–4 lines of chemotherapy and were poly(ADP-ribose) polymerase inhibitor naïve. Participants received niraparib (starting dose, 300 mg) once daily in continuous 28-day cycles until objective disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was confirmed objective response rate (ORR), as assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Safety evaluations included treatment-emergent adverse events (TEAEs).
Results:20 patients were enrolled in the study and included in both efficacy and safety analyses. Median total study duration was 759.5 days. Median dose intensity was 201.3 mg/ day. Confirmed ORR was 60.0% (90% confidence interval [CI]=39.4–78.3); 2 patients had complete response and 10 patients had partial response. Median duration of response was 9.9 months (95% CI=3.9–26.9) and the disease control rate was 90.0% (95% CI=68.3–98.8).The most common TEAEs were anemia (n=15), nausea (n=12), and decreased platelet count (n=11). TEAEs leading to study drug dose reduction, interruption, or discontinuation were reported in 16 (80.0%), 15 (75.0%), and 2 patients (10.0%), respectively.
Conclusion:The long-term efficacy and safety profile of niraparib was consistent with previous findings in the equivalent population in non-Japanese patients. No new safety signals were identified.
